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Obesity, insulin resistance, and type 2 diabetes are associated with a substantially
increased prevalence of vascular fibrosis and stiffness, with attendant increased risk of
cardiovascular and chronic kidney disease. Although the underlying mechanisms and
mediators of vascular stiffness are not well understood, accumulating evidence supports
the role of metabolic and immune dysregulation related to increased adiposity, activation
of the renin angiotensin aldosterone system, reduced bioavailable nitric oxide, increased
vascular extracellular matrix (ECM) and ECM remodeling in the pathogenesis of vascular
stiffness. This review will give a brief overview of the relationship between obesity, insulin
resistance and increased vascular stiffness to provide a contemporary understanding of
the proposed underlying mechanisms and potential therapeutic strategies.
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Introduction
Vascular stiffness is a consequence of pathophysiological alterations involving endothelial cells
(ECs), vascular smooth muscle cells (VSMCs), extracellular matrix (ECM), and other functional
elements of the vessel wall (Brillante et al., 2009; Jia and Sowers, 2014; Villacorta and Chang,
2015). These alterations are believed to occur early and contribute to premature cardiovascular
dysfunction and structural alterations leading to increased risk for cardiovascular disease (CVD)
morbidity and mortality. The Framingham Heart Study of 2232 participants confirmed vascular
stiffness as an independent predictor of CVD morbidity and mortality in the general population,
hypertensive patients, the elderly, and patients with end-stage renal disease (Mitchell et al., 2010).
Further, increased vascular stiffness is an important early marker for CVD and a predictor of
heart attacks and strokes in adults, especially in persons with obesity, insulin resistance and type 2
diabetes mellitus (T2D) (Jia et al., 2014b).
Non-invasive measurements of vascular stiffness usually fall into three categories: (1) analysis
of pulse transit time; (2) wave contour of the arterial pulse; and (3) direct measurement of
arterial geometry and pressure that corresponds to regional, systemic, and local determination
of stiffness (Ray et al., 2014). Recently, the European Society of Hypertension (ESH)/European
Society of Cardiology (ESC) guidelines for the management of arterial hypertension suggested the
measurement of aortic pulse wave velocity (PWV), which is considered the gold standard method
for assessing vascular stiffness, as a tool for assessment of subclinical target organ damage (Mancia
et al., 2013). Typical values of PWV in the aorta range from approximately 5 m/s to >15m/s
(Luft, 2012). A fixed threshold value (12m/s) was proposed as an indication of increased vascular
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stiffness in the 2007 ESH/ESC hypertension guidelines based on
published epidemiological studies (Reference Values for Arterial
Stiffness Collaboration, 2010).
Obesity is associated with vascular remodeling and stiffness
and has been known to predict increased cardiovascular
mortality (Martínez-Martínez et al., 2014). Insulin resistance, a
consequence of obesity, has been also shown as an independent
risk factor for vascular stiffening and other elements of
diabetic vasculopathy (Jia and Sowers, 2014). To this point, the
mechanisms and interactions of overweight/obesity and insulin
resistance in the regulation of vascular stiffness involve a complex
network of interacting factors that are not yet completely
understood. Much work needs to be done to clarify initiating and
potentiating factors and the progression and vascular distribution
of this phenomenon. Therefore, a better understanding of
the mechanisms of vascular stiffening in obesity and insulin
resistance has great clinical significance. In the present review,
we will discuss the roles and mechanisms of vascular stiffness in
patients with obesity and insulin resistance to provide a basis for
improving understanding of potential therapeutic strategies.
Obesity and Insulin Resistance
The overweight/obesity epidemic has led to a marked increase
in the incidence of insulin resistance, T2D, and the cardiorenal
metabolic syndrome (Leopold, 2013). Overweight is defined as
a body mass index (BMI) of 25–29.9, obesity as a BMI > 30,
and severe obesity as a BMI > 40 (or ≥35 in the presence
of comorbidities) (Forte et al., 2012). Currently, approximately
34.4% of adults and children are overweight in the United
States (Forte et al., 2012). Sedentary lifestyle and dietary changes
in combination with genetic predisposition are regarded as
the major risk factors for obesity (Jia et al., 2014a). A strong
association has been observed between obesity and insulin
resistance (Herouvi et al., 2013). It has been postulated that
with increased abdominal adiposity there is greater lipolytic
activity leading to an increase in free fatty acids (FFA), which
may inhibit insulin secretion and insulin-stimulated glucose
uptake and thus increase the risk for insulin resistance and
T2D (Forte et al., 2012; DeMarco et al., 2014). Meanwhile, there
is also increased liver synthesis of triglycerides in response to
the increased circulating FFA and increased hepatic production
of glucose resulting in hyperinsulinemia (Forte et al., 2012;
DeMarco et al., 2014). Thus, increased attention to weight
control may improve insulin sensitivity and help prevent
CVD. However, studies have found an obesity paradox that
overweight and obese people have a better prognosis in heart
failure, hypertension, end-stage renal disease, and mortality than
normal-weight individuals (Morse et al., 2010). For example,
approximately 10–25% of obese individuals are metabolically
healthy due to preserved insulin sensitivity (Blüher, 2010).
These reports suggest that visceral adipose tissue and ectopic
fat deposition play an important role in development of insulin
resistance in human obesity independently of total body fat
mass. Thus, BMI may not be the most accurate index for
obesity.
Vascular Stiffness in Insulin Resistance
and Obesity
Obesity and insulin resistance interact and impair vascular
function and structure and are linked to endothelial dysfunction,
increased artery intima media thickness, and increased vascular
stiffness (Herouvi et al., 2013) (Figure 1). It is well accepted
that obesity is associated with increased vascular stiffness and
associated CVD. Obese individuals exhibit increased vascular
stiffness compared with non-obese individuals, and weight loss
improves arterial compliance (Villacorta and Chang, 2015). A
recent population study showed that skin-fold thickness is a
predictor of arterial stiffness in hypertensive patients (Selcuk
et al., 2013). Other recent studies implicate dysfunctional
perivascular adipose tissue (PVAT) adjacent to the vessel wall
in the pathogenesis of vascular stiffness. The PVAT serves
not only as a structural component present in most arteries
but also as a source of an abundance of molecules with
varied paracrine effects (Villacorta and Chang, 2015). In the
setting of obesity and insulin resistance, adipocyte hyperplasia
is associated with both the infiltration of pro-inflammatory
immune cells and a reduced expression of anti-inflammatory
factors in the PVAT (Aroor et al., 2013b). The Framingham
Offspring and Third Generation cohorts further support the
notion that PVAT volume is associated with higher thoracic
and abdominal aortic dimensions and increased stiffness even
after adjusting for age, sex, and CVD risk factors including
BMI and visceral adipose tissue volume (Thanassoulis et al.,
2012). These findings support the notion that obesity and
PVAT are important contributors to the pathogenesis of vascular
stiffness.
Epidemiological studies have demonstrated that
hyperinsulinemia or insulin resistance is an independent
risk factor for vascular stiffening and other elements of
diabetic vasculopathy (Aroor et al., 2013a; Padilla et al., 2015).
A report from a cross-sectional study of the relationships
between arterial stiffness indexes and serum insulin and glucose
tolerance measurements in a biracial population of 4701 men
and women aged 45–64 demonstrated these individuals were
at increased risk for atherosclerosis. It was also shown that
individuals with borderline abnormal glucose intolerance or
non-insulin-dependent diabetes mellitus had stiffer arteries
than their counterparts with normal glucose tolerance and the
decreased elasticity was independent of artery wall thickness
(Salomaa et al., 1995). It was suggested that interactive effects
of elevated glucose, insulin, and triglycerides may have a
combined and synergistic impact on arterial stiffness and play
an important role in the early pathophysiology of macro-
vascular disease in patients with T2D (Cote et al., 2015).
Vascular stiffening in association with obesity and insulin
resistance has been observed in all age groups, including
children (Tounian et al., 2001; van Popele et al., 2006; Ho
et al., 2011). Therefore, obesity-related insulin resistance or
T2D is considered a powerful risk factor for occurrence of
vascular stiffness and adverse CVD events in both children and
adults.
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FIGURE 1 | Proposed mechanisms of vascular stiffness in obesity,
insulin resistance, and type 2 diabetes. EC, endothelial cell; VSMC,
vascular smooth muscle cell; AGE, advanced glycation end products;
MMPs, matrix metalloproteinase; TG2, tissue transglutaminase; Ang II,
angiotensin II; MR, mineralocorticoid receptor; TxA2, thromboxane A2;
ENaC, epithelial Na+ channel; IL, interleukin; TNF, tumor necrosis factor; NO,
nitric oxide; MCP-1, monocyte chemotactic protein-1; CRP, C- reactive
protein; TGF-β, transforming growth factor- β.
Vascular Stiffness Related Cardiovascular
Risk
Data from the Framingham study have established an increased
incidence of CVD events with increasing weight in both
men and women (Hubert et al., 1983), and these CVD has
been strongly associated with insulin resistance and vascular
stiffness (DeMarco et al., 2015). However, vascular stiffness
independently predicts cardiovascular events (Matsuoka et al.,
2005), since increased vascular stiffness is significantly associated
with damage to target organs such as the heart, kidney, liver, and
brain (Schiffrin, 2004). For example, stiffening of central arteries
increases systolic pressure, and decreases diastolic pressure,
resulting in increased pulse afterload leading to an increase in
left ventricular mass and myocardial oxygen demand. Further,
the decrease in diastolic pressure is associated with reduced
coronary blood flow during the diastole. These changes have
been associated with left ventricular remodeling and fibrosis
and thereby cause left ventricular diastolic dysfunction and
development of coronary artery disease (Jia et al., 2014b; Bostick
et al., 2015). Hypertension is regarded as a major risk factor
for vascular remodeling and development of vascular stiffness.
Remodeling associated with hypertension has been viewed as
an adaptive process involving an increased wall-to-lumen width
ratio in response to long-term changes in hemodynamic forces
(Weisbrod et al., 2013). However, recent analysis from the
Framingham Heart Study and from other studies (Weisbrod
et al., 2013; DeMarco et al., 2015) indicated that aortic stiffness
precedes hypertension, and progressive structural and functional
changes in the aorta may exist prior to the development of
increased levels of blood pressure (Liao and Farmer, 2014).
Furthermore, initial blood pressure was not independently
predictive of subsequent vascular stiffening measured in the
same individuals following 4–10 years observation (Kaess
et al., 2012). This is an important controversial point in the
field and underscores the need to understand the cause and
effect relationship between hypertension and aortic stiffness
(Liao and Farmer, 2014). Despite this, the evidence suggests
that early detection of arterial stiffening certainly helps to
identify and reduce risk factors for vascular stiffness and CVD
progression.
Mechanism of Vascular Stiffness
Obesity, hypertension, dyslipidemia, insulin resistance and
activation of renin- angiotensin-aldosterone (RAAS) and
sympathetic nervous (SNS) systems are all components of
the cardiorenal metabolic syndrome, which is associated with
vascular stiffness (Sowers, 2013; Jia and Sowers, 2014; Jia et al.,
2014b). Dysregulation of ECs, VSMCs, ECM, and adaptive
immune responses in the cardiorenal metabolic syndrome all
play a key role in the development of vascular stiffness (Figure 1).
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Adiposity
Excess adipose tissue, in particular abdominal adipose tissue,
has been closely linked to the development of vascular stiffness
and cardiovascular disease (Strasser et al., 2015). Abnormal
production of adipokines participates in the pathogenesis
of obesity- and insulin resistance-associated comorbidities,
including vascular stiffness and hypertension. Indeed, adipocytes
may produce over fifty active substances including monocyte
chemotactic protein-1 (MCP-1), tumor necrosis factor-α
(TNF-α), interleukin-6 (IL-6), C-reactive protein (CRP),
and angiotensin II (Ang II), all of which are released into
the circulation and are involved in the regulation of insulin
sensitivity, immune responses, vascular function, arterial blood
pressure, coagulation and acute inflammation (Zapolski et al.,
2011; Jia et al., 2014c) (Figure 1). For example, MCP-1 plays
a key role in macrophage infiltration into adipose tissue of
obese individuals and is associated with development of insulin
resistance (Kanda et al., 2006). Our previous studies demonstrate
that consumption of a western diet high in fat and fructose
promotes adipose tissue inflammation and results in reduced
production of adiponectin, as well as increased secretion
of resistin and other inflammatory cytokines, all of which
contribute to systemic and cardiac insulin resistance, metabolic
cardiomyopathy, and vascular stiffness (Bostick et al., 2014,
2015). Of relevance, resistin, TNF-α, CRP, and IL-6 all inhibit
insulin metabolic signaling in these tissues and promote cardiac
and vascular stiffness through activation of mitogen activated
protein kinase (MAPK), protein kinase C (PKC), rapamycin
(mTOR)/S6 kinase 1 (S6K1) and suppressor of cytokine signaling
3mediated proteasomal degradation of insulin receptor substrate
1 (IRS-1) (Bender et al., 2013).
EC and VSMC Dysfunction
The complex interactions between EC and VSMC are important
for the modulation of vascular function and tone. For example,
EC production of nitric oxide (NO) has a vasodilatory effect
and anti-atherogenic properties, including inhibition of VSMC
proliferation and migration, platelet activation and adhesion and
leukocyte adhesion and migration (Herouvi et al., 2013). To this
point, NO diffuses into neighboring VSMCs, activating guanylyl
cyclase to produce cyclic guanosine monophosphate (cGMP)
and activate kinases responsible for vascular relaxation (Bender
et al., 2013). Indeed, vascular tone is tightly controlled by EC
secretion of vasodilatory substances, such as NO, endothelium-
derived hyperpolarizing factor (EDHF), prostacyclin (PGI2), and
vasoconstrictor substances, such as angiotensin II (Ang II), and
thromboxane A2 (Creager et al., 2003; Mudau et al., 2012).
Further, EC dysfunction and increased stiffness (Fels et al., 2014;
Oberleithner, 2014) have been proposed to mediate the changes
in the vasculature that lead to fibrosis and stiffness in obesity,
insulin resistance and T2D.
VSMCs are the predominant cell type found in the medial
layer of the vessel wall and are a target of insulin metabolic
and growth signaling (Doronzo et al., 2004; Jia and Sowers,
2014), as well as the target of most vascular therapies aimed
at reducing mean arterial pressure. Insulin normally induces
vasodilation in VSMCs through insulin metabolic signaling that
includes IRS-1/phosphatidylinositide 3-kinases (PI3K), protein
kinase B (Akt) and cGMP signaling pathways. This signaling
leads to a reduction of free intracellular calcium and reduction
in contractile apparatus calcium sensitivity (Doronzo et al.,
2004). Thus, insulin resistance in VSMCs impairs vascular
vasodilation. Indeed, studies from insulin resistant obese Zucker
rats have shown that VSMCs from these rats manifested greater
concentrations of reactive oxygen species and have impaired
activation of the NO/cGMP/PKG pathway when compared
to VSMC from insulin-sensitive Zucker Lean rats (Doronzo
et al., 2004). Our recent data also showed that a western
diet high in fat and refined carbohydrates impaired mouse
aortic endothelium-dependent and endothelium-independent
vasodilation by protein kinase B/endothelial NO synthase
(eNOS) signaling pathways (DeMarco et al., 2015). These
observations provide a biochemical basis by which obesity and
insulin resistance in vascular cells could lead to development of
vascular stiffening.
ECM
Alterations in ECM composition and structure are important
contributors to vascular compliance and vascular stiffness.
Transforming growth factor (TGF-β) and connective tissue
growth factor (CTGF) are well-known profibrotic factors that
can stimulate synthesis of ECM proteins, such as fibronectin and
collagens, under conditions of obesity, insulin resistance, and
T2D (Jia et al., 2015). Studies have also found that advanced
glycosylation end-products (AGEs) enhance collagen content
and cross linking, and induce changes in mechanical properties
of the ECM (Jia et al., 2014b). Indeed, AGEs promote a
decrease in the rate of ECM degradation, an increase in the
production of nascent ECM and an increase in cross-linking of
the extracellular proteins (Torjesen et al., 2014). In the context
of vascular stiffening, the matrix metalloproteinases (MMPs)
are involved in the regulation of the structural integrity of the
ECM. The MMPs are a family of enzymes that proteolytically
degrade ECM and participate in this remodeling of vessel wall
(DeMarco et al., 2015). The increase in MMPs in vessels from
insulin resistant and diabetic animals has been reported to be
accompanied by pronounced generation of angiostatin, and the
reduction of microvascular density was associated with impaired
vasorelaxation (Chung et al., 2009; Paik et al., 2013; Wang et al.,
2014). In addition, tissue transglutaminase (TG2) plays a key
role in promoting vascular stiffness by increasing cell surface
and ECM cross linking activity in the vasculature (Deenadayalu
et al., 2012). Thus, deleterious remodeling of ECM results from
numerous maladaptive processes that are not limited purely to
changes in content of a particular ECM protein type.
RAAS
It has been recognized that inappropriate neurohumoral
activation including both Ang II and aldosterone promote
vascular stiffness in obesity and T2D. Both hormones directly
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modulate vascular stiffness by upregulation of nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase activity and
reduction of NO bioavailability, thereby promoting oxidative
stress and vascular dysfunction (Manrique et al., 2013). Recently,
it was shown that prolonged exposure to increasedmitochondrial
oxidative stress decreased aortic compliance and induced cardiac
dysfunction (Zhou et al., 2012). Specifically, the data elucidated
the significance of lifelong superoxide dismutase 2 deficiency on
the phenotype, function, and molecular signaling pathways of
aortic SMCs. These results further showed how oxidative stress
promotes aortic stiffening by inducing vascular wall remodeling,
intrinsic changes in SMC stiffness, and aortic SMC apoptosis
(Zhou et al., 2012). Aldosterone and increased salt in the
diet also increase epithelial Na+ channel (ENaC) expression
on the EC surface leading to reduced NO production that is
associated with increases in cortical stiffness of the cytoskeleton
(Kusche-Vihrog et al., 2014) (Figure 1). Some of our studies
have explored the signaling pathways by which enhanced tissue
RAAS contributed to insulin resistance and cardiovascular
stiffness. For example, Ang II increases serine phosphorylation
of IRS-1 and inhibits the insulin-stimulated phosphorylation
of eNOS through activation of S6K1 signaling pathway. Also,
an inhibitor of mTOR (rapamycin) attenuates the Ang II-
stimulated phosphorylation of p70S6K and IRS-1 and blocks the
ability of Ang II to impair insulin-stimulated phosphorylation
of eNOS and NO dependent-arteriole vasodilation (Kim et al.,
2012). Thus, we conclude that activation of mTOR/p70S6K
by Ang II and aldosterone in vascular ECs and VSMCs may
contribute to the impairment of insulin-stimulated vasodilation
through phosphorylation of IRS-1 (Cote et al., 2013). Indeed,
adipose tissue expresses all components of RAAS, such as
renin, angiotensin converting enzyme 1, angiotensin converting
enzyme 2, and angiotensin receptor (AT) 1, AT2, as well as
the Mas receptor (Grobe et al., 2013). Global knockout (KO)
of AT1 resulted in the attenuation of weight gain and adipose
deposition during high-fat feeding. Conversely, AT2 KO had
no obvious effect on adipose deposition (Grobe et al., 2013).
Furthermore, Mas receptor KO, which is the receptor Ang-(1–
7), has a complex effect on body composition, including an
increase in abdominal fat mass, and decreased glucose tolerance
and insulin sensitivity (Santos et al., 2008). Thus, further studies
are necessary to understand RAAS in the pathogenesis of vascular
stiffness.
Maladaptive Immune Responses
Vascular stiffness is associated with chronic inflammatory disease
in the vessel wall characterized by an activation of both the
innate and adaptive immune systems, which are composed
of diverse cellular components, including granulocytes, mast
cells, monocytes, macrophages, and natural killer cells (Aroor
et al., 2013b) (Figure 1). For example, activated T cells can
be sub-typed according to their cytokine profile. T helper
(Th) 1 cells secrete IL-2, TNF-β, and IFN-γ, whereas Th2
cells typically produce IL-4, -5, -6, and -10 (Ait-Oufella et al.,
2006). Increased Th cell secretion of cytokines, chemokines,
and growth factors leads to an inflammatory process that may
lead to fragmentation of elastic membranes and destruction
of cell-protective matrix layers. However, CD4+CD25+Foxp3+
regulatory T cells (Tregs) can protect the vascular cells by
immunosuppression, cell contact–dependent suppression, and
functional modification or killing of activated protein C (He
et al., 2010). Furthermore, macrophage polarization toward an
enhanced M1 pro-inflammatory response and suppression of
an M2 anti-inflammatory response occurs in insulin resistance
and obesity (Aroor et al., 2013a,b). The pro-inflammatory M1
macrophages secrete inflammatory cytokines such as TNF-α
that cause insulin resistance. In contrast, M2 macrophages
secrete IL-10, which can improve the insulin signaling impaired
by pro-inflammatory cytokines (Aroor et al., 2013a,b). It
has been shown that an acute high fat diet boosts growth
and promotes hematopoietic expansion and differentiation
in fetal mice, including lymphoid cells (CD3þ/B220þ) and
myeloid cells (Gr1þ/Ter119þ) (Kamimae-Lanning et al., 2015).
However, obesity diminishes endothelial progenitor cells level,
impaired the recovery of damaged endothelium, and suppressed
endothelial progenitor cell angiogenesis ability, resulting in left
ventricular remodeling and cardiac dysfunction (Tsai et al., 2012).
The link between adaptive immune responses, hematopoietic
abnormality, and vascular stiffness offers possibilities for
identification of the origins of vascular dysfunction and altered
vascular stiffness and may allow for development of novel
targeted therapeutic interventions.
Gender, Vascular Stiffness, Insulin
Resistance, and Obesity
Non-diabetic premenopausal women exhibit lower incidence of
cardiovascular complications compared to age matched men.
However, this protection is lost under the setting of obesity
and T2D (Manrique et al., 2013; DeMarco et al., 2015). Indeed,
women display increased risk for diastolic dysfunction than men
in the setting of obesity and T2D. Moreover, higher ventricular
stiffness seen in obese women may contribute to increased
incidence of diastolic dysfunction (DeMarco et al., 2015; Jia et al.,
2015). Further, left ventricular mass correlates positively with
insulin resistance and glucose intolerance, especially in women
(Manrique et al., 2013). Therefore, significance of studies focused
on sex differences in cardiovascular dysfunction is increasingly
recognized (Clayton and Collins, 2014).
Although the mechanisms that contribute to vascular
stiffness in obese premenopausal women are poorly understood,
upregulation of RAAS signaling may be important in this
regard (Aroor et al., 2013a). Aldosterone levels were found
to be higher in women and to be positively associated with
cardiac structural remodeling in females, but not in males
(Vasan et al., 2004). Aldosterone promotes cardiac and vascular
stiffness and administration of the aldosterone antagonist
spironolactone prevents both cardiac and vascular stiffness in
a clinically translational model of western diet-induced obesity
in female mice (Bostick et al., 2015; DeMarco et al., 2015).
The improvement in vascular stiffness is also accompanied by
suppression of M1 macrophage polarization, decreased vascular
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oxidative stress and improvement in insulin metabolic signaling
(DeMarco et al., 2015).
Conclusion
Vascular stiffness is increased in conditions of insulin resistance
and obesity and independently increases the risk of developing
hypertension, coronary heart disease, and CVD morbidity
and mortality. The underlying pathophysiology of vascular
stiffness in insulin resistance and obesity involves activation
of RAAS, adipocyte inflammation, abnormalities in vascular
cells, ECM and maladaptive immune responses, all of which
increase the risk of vascular stiffness associated CVD events
(Figure 1). Future therapeutic strategies should emphasize the
need to control glycemia, as well as adopt healthier lifestyles
incorporating better nutrition, weight control, more physical
activity and cigarette smoking cessation. A better understanding
of the underlying mechanisms leading to vascular stiffness and
associated cardiovascular diseases may disclose new strategies to
controlling the morbidity and mortality in these patients.
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